S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

CVE:NVH - Novoheart Stock Price, Forecast & News

C$0.62
+0.01 (+1.64 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
C$0.62
Now: C$0.62
C$0.62
50-Day Range
C$0.32
MA: C$0.52
C$0.62
52-Week Range
C$0.21
Now: C$0.62
C$0.62
Volume11,140 shs
Average Volume41,484 shs
Market CapitalizationC$116.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States, Canada, and Hong Kong. It offers an array of next-generation human heart tissue prototypes. The company provides a range of bioengineering technologies known as the MyHeart platform, including the human mini-heart 'novoHeart' that is capable of pumping and ejecting fluid. Its MyHeart platform develops cell-based cardiac regenerative therapies. The company's MyHeart products include human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. It also provides screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. The company is based in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-398 3170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$337,843.00
Cash FlowC$0.11 per share
Book ValueC$0.18 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$116.90 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NVH News and Ratings via Email

Sign-up to receive the latest news and ratings for NVH and its competitors with MarketBeat's FREE daily newsletter.


Novoheart (CVE:NVH) Frequently Asked Questions

What is Novoheart's stock symbol?

Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH."

Has Novoheart been receiving favorable news coverage?

News stories about NVH stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novoheart earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Novoheart.

Who are some of Novoheart's key competitors?

What other stocks do shareholders of Novoheart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include InVitae (NVTA) and Natera (NTRA).

Who are Novoheart's key executives?

Novoheart's management team includes the folowing people:
  • Dr. Ronald Li B.Sc. (Hons), Ph.D., Scientific Co-Founder, CEO & Director (Age 48)
  • Prof. Kevin Costa B.S., Ph.D., Chief Scientific Officer & Scientific Co-Founder (Age 53)
  • Dr. Camie Chan B.S., B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director (Age 45)
  • Prof. Michelle Khine, Scientific Co-Founder & Member of Scientific Advisory Board
  • Dr. Bill A. Williams, Sr. VP of Commercial Operations

How do I buy shares of Novoheart?

Shares of NVH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Novoheart's stock price today?

One share of NVH stock can currently be purchased for approximately C$0.62.

How big of a company is Novoheart?

Novoheart has a market capitalization of C$116.90 million and generates C$337,843.00 in revenue each year. View Additional Information About Novoheart.

What is Novoheart's official website?

The official website for Novoheart is http://www.novoheart.com/.

How can I contact Novoheart?

The company can be reached via phone at 604-398 3170.


MarketBeat Community Rating for Novoheart (CVE NVH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Novoheart and other stocks. Vote "Outperform" if you believe NVH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Commodities

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel